Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone

Journal of Bone and Mineral Research

Volumn 26, Issue 2, 2011, Pages 270-276

  Diab, Tamim ^a,b,c   Wang, Jason ^b,c   Reinwald, Susan ^a   Guldberg, Robert E ^b,c   Burr, David B ^a,d  

^a INDIANA UNIVERSITY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^d Indiana University Purdue University Indianapolis   (United States)

Author keywords

ALENDRONATE; BIOMECHANICAL PROPERTIES; DENSITY; FRACTURE; RALOXIFENE

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE TURNOVER; CANCELLOUS BONE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; NONHUMAN; RAT; RIGIDITY; SPRAGUE DAWLEY RAT; VERTEBRA BODY;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY; DRUG THERAPY, COMBINATION; HUMANS; LUMBAR VERTEBRAE; MODELS, STATISTICAL; OSTEOPOROSIS; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79251509585     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.197     Document Type: Article

References (31)

1. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD., Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1-10.
2. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280: 2077-2082.
3. Allen MR, Iwata K, Sato M, Burr DB., Raloxifene enhances vertebral mechanical properties independent of bone density. Bone. 2006; 39: 1130-1135.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-1541.
5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 18: 282: 637-645.
6. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-289.
7. Riggs BL, Melton LJ 3rd., Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res. 2002; 17: 11-14.
8. Allen MR, Gineyts E, Leeming D, Burr DB, Delmas PD., Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporosis Int. 2008; 19: 329-337.
9. Allen MR, Hogan HA, Hobbs WA, Koivuniemi AS, Koivuniemi MC, Burr DB., Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology. 2007; 148: 908-913.
10. Allen MR, Burr DB., Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int. 2008; 19: 95-99.
11. Allen MR, Burr DB., Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J Bone Miner Res. 2007; 22: 1759-1765.
12. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E., Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87: 985-992.
13. Iwata K, Li J, Follet H, Phipps RJ, Burr DB., Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone. 2006; 39: 1053-1058.
14. Fuchs RK, Phipps RJ, Burr DB., Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res. 2008; 23: 1689-1697.
15. Allen MR, Iwata K, Phipps R, Burr DB., Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone. 2006; 39: 872-879.
16. Buie HR, Campbell GM, Klinck RJ, MacNeil JA, Boyd SK., Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis. Bone. 2007; 41: 505-515.
17. Reinwald S, Peterson RG, Allen MR, Burr DB., Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab. 2009; 296: E765-74.
18. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB., Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001; 28: 524-531.
19. Foldes J, Shih MS, Parfitt AM., Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res. 1990; 5: 1063-1067.
20. Diab T, Allen MR, Burr DB., Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra. Osteoporos Int. 2009; 20: 647-652.
21. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
22. Mastbergen SC, Pollmeier M, Fischer L, Vianen ME, Lafeber FP., The groove model of osteoarthritis applied to the ovine fetlock joint. Osteoarthritis Cartilage. 2008; 16: 919-928.
23. Jee WSS, Li XJ, Ke HZ., The skeletal adaptation to mechanical usage in the rat. In: Jee WSS (ed.) The Aged Rat Model for Bone Biology Studies. Cells and Materials. 1991; (Suppl 1): pp. 131-143.
24. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF., The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res. 1995; 10: 211-221.
25. Kimmel DB, Moran EL, Bogoch ER., Animal models of osteopenia or osteoporosis. In:, Yuehuei HA, Friedman RJ, eds. Animal Models in Orthopaedic Research. Boca Raton, FL: CRC Press, 1999: 280-305.
26. Grynpas M., Age and disease-related changes in the mineral of bone. Calcif Tissue Int. 1993; 53: S57-64.
27. DeGroot J., The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol. 2004; 4: 301-305.
28. Nazarian A, Cory E, Müller R, Snyder BD., Shortcomings of DXA to assess changes in bone tissue density and microstructure induced by metabolic bone diseases in rat models. Osteoporos Int. 2009; 20: 123-132.
29. Nazarian A, Snyder BD, Zurakowski D, Müller R., Quantitative micro-computed tomography: a non-invasive method to assess equivalent bone mineral density. Bone. 2008; 43: 302-311.
30. Wronski TJ, Dann LM, Scott KS, Cintron M., Long-term effects of ovariectomy and aging on the rat skeleton. Calcif Tiss Int. 1989; 45: 360-366.
31. Wronski TJ, Cann LM, Horner SL., Time course of vertebral osteopenia in ovariectomized rats. Bone. 1989; 10: 295-301.